Get the Stockscreener App
10.53
0.48%
0.05
Arcus Biosciences Inc stock is traded at $10.53, with a volume of 726.94K.
It is up +0.48% in the last 24 hours and up +14.96% over the past month.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
See More
Previous Close:
$10.48
Open:
$10.55
24h Volume:
726.94K
Relative Volume:
0.77
Market Cap:
$1.12B
Revenue:
$247.00M
Net Income/Loss:
$-249.00M
P/E Ratio:
-3.4078
EPS:
-3.09
Net Cash Flow:
$-267.00M
1W Performance:
+1.35%
1M Performance:
+14.96%
6M Performance:
-4.88%
1Y Performance:
-40.47%
1-Day Range:
$10.48
$11.00
1-Week Range:
$9.81
$11.00
52-Week Range:
$6.50
$18.98
Arcus Biosciences Inc Stock (RCUS) Company Profile
Name
Arcus Biosciences Inc
Sector
Industry
Phone
(510) 694-6200
Address
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
10.53 | 1.11B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-21-24 | Initiated | H.C. Wainwright | Neutral |
| Oct-08-24 | Initiated | Wells Fargo | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Nov-23-20 | Initiated | Evercore ISI | Outperform |
| Apr-03-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Sep-27-19 | Initiated | Mizuho | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Oct-09-18 | Initiated | Wedbush | Outperform |
| Apr-09-18 | Initiated | Citigroup | Buy |
| Apr-09-18 | Initiated | Goldman | Neutral |
| Apr-09-18 | Initiated | Leerink Partners | Outperform |
View All
Arcus Biosciences Inc Stock (RCUS) Latest News
Clinical-Stage Biotech Arcus Lines Up Citi, Morgan Stanley, and H.C. Wainwright September Conferences - Stock Titan
Mizuho raises Arcus Biosciences stock price target on casdatifan potential By Investing.com - Investing.com Canada
Will Arcus Biosciences Inc. Sustain Its Chart BreakoutGDP Growth & Fast Gain Swing Trade Alerts - classian.co.kr
Will Arcus Biosciences Inc. benefit from rate cutsWeekly Investment Summary & Reliable Breakout Stock Forecasts - thegnnews.com
Arcus Biosciences Inc. Stock Recovery Path — Analyst Breakdown2025 Earnings Impact & Community Consensus Picks - 선데이타임즈
Watch for Bullish Crossover in Arcus Biosciences Inc.Portfolio Value Summary & High Accuracy Swing Entry Alerts - sundaytimes.kr
Jim Cramer on Arcus Biosciences: “Let This Be Your Speculation” - MSN
Wyckoff Accumulation Phase Possible in Arcus Biosciences Inc.Earnings Performance Report & Daily Technical Forecast Reports - newsyoung.net
Candlestick signals on Arcus Biosciences Inc. stock today2025 Market Outlook & Momentum Based Trading Signals - Newser
Using RSI to spot recovery in Arcus Biosciences Inc.Gap Down & Weekly High Potential Alerts - Newser
Identifying reversal signals in Arcus Biosciences Inc.July 2025 PostEarnings & AI Based Buy/Sell Signal Reports - Newser
Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2 - MSN
Will breakout in Arcus Biosciences Inc. lead to full recoveryQuarterly Trade Summary & Fast Entry High Yield Tips - Newser
Arcus Biosciences’ SWOT analysis: stock’s potential hinges on HIF-2alpha data - Investing.com
Jim Cramer Recommends Uranium Energy Corp., Warns Against Overreliance on Arcus Biosciences. - AInvest
Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus - Benzinga
What machine learning models say about Arcus Biosciences Inc.Weekly Profit Report & Expert Approved Trade Ideas - Newser
Why Arcus Biosciences Inc. stock attracts strong analyst attentionWeekly Trade Analysis & Fast Moving Stock Trade Plans - Newser
New Product Launches: Will They Boost Arcus Biosciences Inc. Stock in 2025July 2025 Big Picture & Real-Time Chart Breakout Alerts - Newser
What institutional flow reveals about Arcus Biosciences Inc.Earnings Growth Report & Risk Managed Investment Entry Signals - Newser
Will Arcus Biosciences Inc. Hold Gains Into CloseReliable Alerts for Daily Stock Movers Released - beatles.ru
Arcus Biosciences (NYSE:RCUS) Upgraded at Wall Street Zen - Defense World
How to escape a deep drawdown in Arcus Biosciences Inc.Free Smart Trade Plans With Risk Protection - Newser
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Cantor Fitzgerald Issues Positive Forecast for RCUS Earnings - Defense World
Wedbush Forecasts Lower Earnings for Arcus Biosciences - Defense World
Q3 EPS Forecast for Arcus Biosciences Reduced by Analyst - Defense World
Custom watchlist performance reports with Arcus Biosciences Inc.AI Volatility Forecast and Risk Monitor - Newser
Arcus Biosciences Q2 Earnings and Catalysts Ahead: A Risky Buy for 12 Months - AInvest
Arcus BiosciencesA Risky Buy Ahead Of Pivotal, Catalyst Rich 12 Months (NYSE:RCUS) - Seeking Alpha
Trapped Investors in Arcus Biosciences Inc. Await Breakout SignalNews Based Entry Opportunity Alerts Detected - beatles.ru
Arcus Biosciences, Inc. (NYSE:RCUS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Zurcher Kantonalbank Zurich Cantonalbank Buys 2,524 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Gilead and Arcus Advance Promising Colorectal Cancer Study - TipRanks
Arcus Biosciences Tops Revenue Forecasts And Drives Pipeline Growth - Finimize
Gilead and Arcus Biosciences’ Promising Study on Advanced Gastrointestinal Cancers - TipRanks
A Quick Look at Today's Ratings for Arcus Biosciences(RCUS.US), With a Forecast Between $14 to $52 - 富途牛牛
Wells Fargo Adjusts Price Target for Arcus Biosciences (RCUS) | - GuruFocus
H.C. Wainwright Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
Morgan Stanley Lifts Price Target on Arcus Biosciences to $23 From $22, Keeps Overweight Rating - MarketScreener
Arcus Biosciences (RCUS) Surges 10% on Q2 Earnings Beat and Pipeline Momentum - AInvest
Decoding Arcus Biosciences Inc (RCUS): A Strategic SWOT Insight - GuruFocus
Arcus Biosciences Reports Strong Q2 2025 Results - TipRanks
Arcus Biosciences earnings beat by $0.01, revenue topped estimates - Investing.com Canada
Arcus Biosciences Q2 revenue beats analyst expectations - MarketScreener
Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update - Stock Titan
Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Is Arcus Biosciences (NYSE:RCUS) Using Debt In A Risky Way? - 富途牛牛
When is Arcus Biosciences Inc. stock expected to show significant growthIdentify undervalued stocks ready to soar - Jammu Links News
How volatile is Arcus Biosciences Inc. stock compared to the marketTremendous gains - Jammu Links News
What are the technical indicators suggesting about Arcus Biosciences Inc.Free Wealth Planning Blueprint - Jammu Links News
Arcus Biosciences Inc Stock (RCUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Arcus Biosciences Inc Stock (RCUS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ROSEN TERRY J | Chief Executive Officer |
Feb 27 '25 |
Buy |
10.18 |
19,800 |
201,465 |
2,554,160 |
| GILEAD SCIENCES, INC. | 10% Owner |
Feb 18 '25 |
Buy |
11.00 |
1,363,636 |
14,999,996 |
31,424,760 |
| Goeltz II Robert C. | Chief Financial Officer |
Dec 31 '24 |
Sale |
15.00 |
3,594 |
53,910 |
60,138 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):